Tarsus Pharmaceuticals (id:8060 TARS)
48.24 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 1:51:46 PM)
Exchange closed, opens in 19 hours 38 minutes
About Tarsus Pharmaceuticals
Market Capitalization 1.78B
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
| Headquarters (address) |
15440 Laguna Canyon Road Irvine 92618 CA United States |
| Phone | 949 409 1801 |
| Website | https://www.tarsusrx.com |
| Employees | 244 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | TARS |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 15.60 - 52.99 |
| Market Capitalization | 1.78B |
| P/E trailing | -10.44 |
| P/E forward | -21.60 |
| Price/Sale | 13.76 |
| Price/Book | 7.50 |
| Beta | 1.00 |
| EPS | -4.47 |
| EPS United States (ID:6, base:3402) | 24.22 |